After the US approval, BioNTech and its partner Pfizer have received the emergency approval in the European Union for their COVID-19 vaccine BNT162 since yesterday. Surprisingly, that did not happen again, which is also noticeable in the price reaction of the BioNTech share on the stock exchange we reported. Even today, little is happening. In XETRA trading, the biotech share is currently trading slightly higher at EUR 87.99. You can read more about the technical position of the BioNTech share based on the NASDAQ prices in the afternoon 4investors.
On Tuesday morning after yesterday’s approval, the focus was first on the next steps towards vaccinations in Europe. The distribution of vaccine doses within the EU depends, among other things, on the population of the individual country, according to a BioNTech press conference in the morning. The Mainz team is working flat out on the preparations for the vaccinations. Production is already under way – among others at the also listed partner Dermapharm. 50 million doses of BNT162 will be available worldwide in 2020 and 1.3 billion in the coming year. BioNTech’s Marburg location, which Novartis bought, is scheduled to start production in February. Deliveries could start tomorrow, among other things, final quality controls are currently being carried out